Skip to main content
SpringerLink
Log in

Nail Changes with Targeted Antineoplastic Drugs

  • Chapter
  • First Online:
Advances in Nail Disease and Management

Part of the book series: Updates in Clinical Dermatology ((UCD))

  • 556 Accesses

Abstract

In the last years, new oncology drugs, and especially in targeted ones, have been developed. These new drugs, despite their selective and precise mechanism of action, have been associated with adverse events, involving both skin and appendages, especially nails.

In this article, nail changes due to targeted antineoplastic drugs will be discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 99.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Baldo BA, Pham NH. Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch. Cancer Metastasis Rev. 2013;32(3–4):723–61.

    Article  CAS  Google Scholar 

  2. Macdonald JB, et al. Cutaneous adverse effects of targeted therapies: part I: inhibitors of the cellular membrane. J Am Acad Dermatol. 2015;72(2):203–18.

    Article  CAS  Google Scholar 

  3. Robert C, et al. Nail toxicities induced by systemic anticancer treatments. Lancet Oncol. 2015;16(4):e181–9.

    Article  CAS  Google Scholar 

  4. Hackbarth M, et al. Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women’s cancers. Results of a prospective study. Support Care Cancer. 2008;16(3):267–73.

    Article  Google Scholar 

  5. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf.

  6. Lacouture ME, et al. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer. 2010;18(4):509–22.

    Article  Google Scholar 

  7. https://oncologypro.esmo.org/Education-Library/Glossary-of-Medical-Terms/self-care-ADL.

  8. Ho PH, et al. Using a novel scoring system for paronychia related to oncologic treatments (SPOT) for assessing paronychia severity and its correlation with pain index and quality of life. J Eur Acad Dermatol Venereol. 2019;33(1):204–12.

    Article  Google Scholar 

  9. Lacouture ME, Anadkat M, Jatoi A, Garawin T, Bohac C, Mitchell E. Dermatologic toxicity occurring during anti-EGFR monoclonal inhibitor therapy in patients with metastatic colorectal cancer: a systematic review. Clin Colorectal Cancer. 2018;17(2):85–96.

    Article  Google Scholar 

  10. Beech J, et al. Management and grading of EGFR inhibitor-induced cutaneous toxicity. Future Oncol. 2018;14(24):2531–41.

    Article  CAS  Google Scholar 

  11. Kozuki T. Skin problems and EGFR-tyrosine kinase inhibitor. Jpn J Clin Oncol. 2016;46(4):291–8.

    Article  Google Scholar 

  12. Masago K, et al. Relationship between paronychia and drug concentrations of epidermal growth factor receptor tyrosine kinase inhibitors. Oncology. 2018;95(4):251–6.

    Article  CAS  Google Scholar 

  13. Yen CF, Lee YY. Nail braces for severe paronychia induced by epidermal growth factor receptor inhibitors: an alternative to nail extraction. J Am Acad Dermatol. 2018;78(4):e89–90.

    Article  Google Scholar 

  14. Califano R, Tariq N, Compton S, et al. Expert consensus on the management of adverse events from EGFR tyrosine kinase inhibitors in the UK. Drugs. 2015;75(12):1335–48.

    Article  CAS  Google Scholar 

  15. Melosky B, Leighl NB, Rothenstein J, et al. Management of egfr tki-induced dermatologic adverse events. Curr Oncol. 2015;22(2):123–32.

    Article  CAS  Google Scholar 

  16. Dika E, Patrizi A, Ribero S, et al. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma. Eur J Dermatol. 2016;26(3):232–9.

    Article  CAS  Google Scholar 

  17. Manousaridis I, Mavridou S, Goerdt S, et al. Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management. J Eur Acad Dermatol Venereol. 2013;27(1):11–8.

    Article  CAS  Google Scholar 

  18. Sibaud V, Dalenc F, Mourey L, Chevreau C. Paronychia and pyogenic granuloma induced by new anticancer mTOR inhibitors. Acta Derm Venereol. 2011;91(5):584–5.

    Article  CAS  Google Scholar 

  19. Lacouture M, Sibaud V. Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol. 2018;19(Suppl 1):31–9.

    Article  Google Scholar 

  20. Wollina U. Systemic drug-induced chronic paronychia and periungual pyogenic granuloma. Indian Dermatol Online J. 2018;9(5):293–8.

    PubMed  PubMed Central  Google Scholar 

  21. Belum VR, Fischer A, Choi JN, Lacouture ME. Dermatological adverse events from BRAF inhibitors: a growing problem. Curr Oncol Rep. 2013;15(3):249–59.

    Article  CAS  Google Scholar 

  22. Štulhofer Buzina D, Martinac I, Ledić Drvar D, et al. Adverse reaction to cetuximab, an epidermal growth factor receptor inhibitor. Acta Dermatovenerol Croat. 2016;24(1):70–2.

    PubMed  Google Scholar 

  23. Osio A, Mateus C, Soria JC, et al. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. Br J Dermatol. 2009;161(3):515–21.

    Article  CAS  Google Scholar 

  24. Voilliot-Trotot C, Granel-Brocard F, Geoffrois L, et al. Adverse cutaneous effects and quality of life in patients treated with mTOR inhibitors for renal carcinoma. Ann Dermatol Venereol. 2013;140(5):353–62.

    Article  CAS  Google Scholar 

  25. Bitar C, Farooqui MZ, Valdez J, et al. Hair and nail changes during long-term therapy with ibrutinib for chronic lymphocytic leukemia. JAMA Dermatol. 2016;152(6):698–701.

    Article  Google Scholar 

  26. Das A, Podder I, Kumar D. Imatinib-induced transverse melanonychia: an unusual presentation. Indian J Dermatol. 2015;60(4):412–3.

    Article  Google Scholar 

  27. Thapa M, Chaturvedi A. Imatinib-induced melanonychia in a patient of chronic myeloid leukaemia: rarely reported side effect. Postgrad Med J. 2019;96(1135):296–7.

    Article  Google Scholar 

  28. Peuvrel L, Quéreux G, Brocard A, et al. Onychopathy induced by temsirolimus, a mammalian target of rapamycin inhibitor. Dermatology. 2012;224(3):204–8.

    Article  CAS  Google Scholar 

  29. Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005;6(7):491–500.

    Article  CAS  Google Scholar 

  30. Cho YT, Chan CC. Cabozantinib-induced hand-foot skin reaction with subungual splinter hemorrhages and hypertension: a possible association with inhibition of the vascular endothelial growth factor signaling pathway. Eur J Dermatol. 2013;23(2):274–5.

    Article  Google Scholar 

  31. Zuo RC, Apolo AB, DiGiovanna JJ. Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib. JAMA Dermatol. 2015;151(2):170–7.

    Article  Google Scholar 

  32. Capriotti KD, Anadkat M, Choi J. A randomized phase 2 trial of the efficacy and safety of a novel topical povidone-iodine formulation for Cancer therapy-associated Paronychia. Investig New Drugs. 2019;37(6):1247–56.

    Article  CAS  Google Scholar 

  33. Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28(8):1351–7.

    Article  CAS  Google Scholar 

  34. Kobayashi Y, Komatsu Y, Yuki S, et al. Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study. J-STEPP Future Oncol. 2015;11(4):617–27.

    Article  CAS  Google Scholar 

  35. Goto H, Yoshikawa S, Mori K, et al. Effective treatments for paronychia caused by oncology pharmacotherapy. J Dermatol. 2016;43(6):670–3.

    Article  Google Scholar 

  36. Hachisuka J, Yunotani S, Shidahara S, et al. Effect of adapalene on cetuximab-induced painful periungual inflammation. J Am Acad Dermatol. 2011;64(2):e20–1.

    Article  Google Scholar 

  37. Shi VJ, Levy LL, Choi JN. Cutaneous manifestations of nontargeted and targeted chemotherapies. Semin Oncol. 2016;43(3):419–25.

    Article  CAS  Google Scholar 

  38. Sollena P, Mannino M, Tassone F. Efficacy of topical beta-blockers in the management of EGFR-inhibitor induced paronychia and pyogenic granuloma-like lesions: case series and review of the literature. Drugs Context. 2019;8:212–613.

    Article  Google Scholar 

  39. Lacouture ME. Management of dermatologic toxicities. J Natl Compr Cancer Netw. 2015;13(5 Suppl):686–9.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology-Venereology, National and Kapodistrian University of Athens, Medical School, “A. Sygros” Hospital, Athens, Greece

    Dimitrios Rigopoulos & Ionna Triantafilopoulou

Authors
  1. Dimitrios Rigopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ionna Triantafilopoulou
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Nail Diseases Centre, Cannes, France

    Robert L. Baran

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Rigopoulos, D., Triantafilopoulou, I. (2021). Nail Changes with Targeted Antineoplastic Drugs. In: Baran, R.L. (eds) Advances in Nail Disease and Management. Updates in Clinical Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-030-59997-3_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-59997-3_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-59996-6

  • Online ISBN: 978-3-030-59997-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation